Advantages of the molecular structure of aflibercept

Opinion
Video

Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.

Recent Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
Related Content
4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

4DMT announces the publication of preclinical data in Investigative Ophthalmology & Visual Science

Sydney M Crago
December 20th 2024
Article
Spotlighting telemedicine in the year of a pandemic

Spotlighting telemedicine in the year of a pandemic

Alex Delaney-Gesing
October 19th 2020
Podcast
AMD-HALT program receives Eurostars grant for continued investigation of dry AMD gene therapy platform

AMD-HALT program receives Eurostars grant for continued investigation of dry AMD gene therapy platform

Hattie Hayes
December 16th 2024
Article
Exegenesis Bio provides an update on EXG102 and EXG202 for wet AMD

Exegenesis Bio provides an update on EXG102 and EXG202 for wet AMD

Sydney M Crago
December 11th 2024
Article
Outlook Therapeutics reveals preliminary topline results of NORSE EIGHT

Outlook Therapeutics reveals preliminary topline results of NORSE EIGHT

Sydney M Crago
December 6th 2024
Article
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101

Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101

David Hutton
December 6th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.